Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB160
- Development stage
- Phase 3
- Lead developer
- Mayo Clinic
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**AB160** is an investigational approximately 160 nm nano-immunoconjugate comprising albumin-bound paclitaxel nanoparticles noncovalently coated with the anti-VEGF-A monoclonal antibody bevacizumab. It combines paclitaxel-mediated microtubule stabilization and cytotoxicity with VEGF-A neutralization, using bevacizumab to preferentially direct the nanoparticle complex to VEGF-rich tumor tissue. Mayo Clinic conducted a phase I study in unresectable stage IV melanoma and gynecologic malignancies. The melanoma cohort showed no objective responses and was not considered suitable for further development, while the gynecologic-cancer cohort established a recommended phase II dose and showed clinical activity supporting further evaluation.
- Other names
- AB-160AB160AB 160AB-complexAbraxane/bevacizumab complexnab-paclitaxel/bevacizumab nano-immunoconjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AB160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB160.